The following sections will review the development of PARP inhibitors for the treatment of ovarian cancer and the clinical data available for the five best-studied PARP inhibitors: olaparib, rucaparib, niraparib, veliparib, and talazoparib. Here, PARP1 is linked to ovarian carcinoma.